Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$29.4 million.

  • Protalix BioTherapeutics' Enterprise Value fell 715.46% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 715.46%. This contributed to the annual value of -$34.8 million for FY2024, which is 2183.57% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Enterprise Value stood at -$29.4 million for Q3 2025, which was down 715.46% from -$33.4 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Enterprise Value's 5-year high stood at -$20.8 million during Q3 2022, with a 5-year trough of -$76.9 million in Q2 2021.
  • Its 5-year average for Enterprise Value is -$40.0 million, with a median of -$34.8 million in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 11989.14% in 2021, then soared by 6286.2% in 2022.
  • Over the past 5 years, Protalix BioTherapeutics' Enterprise Value (Quarter) stood at -$39.0 million in 2021, then soared by 43.11% to -$22.2 million in 2022, then tumbled by 100.9% to -$44.6 million in 2023, then grew by 21.84% to -$34.8 million in 2024, then increased by 15.68% to -$29.4 million in 2025.
  • Its last three reported values are -$29.4 million in Q3 2025, -$33.4 million for Q2 2025, and -$34.7 million during Q1 2025.